期刊
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
卷 64, 期 -, 页码 116-124出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcdb.2016.08.024
关键词
PIK3CA; Heterogeneity; Lung cancer; PI3K signaling pathway; Human cancer
资金
- Shanghai Leading Academic Discipline Project [B115]
- Zhongshan Distinguished Professor Grant
- National Nature Science Foundation of China [91230204, 81270099, 81320108001, 81270131, 81400035, 81570075, 81500058, 81500025]
- Shanghai Committee of Science and Technology [12JC1402200, 12431900207, 11410708600]
- Zhejiang Provincial Natural Science Foundation [Z15H010002]
- Zhejiang Provincial Science Technology Department Foundation [WKJ-ZJ-1526]
Phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) plays a crucial role in the initiation and progress of cancerous tumors through the overexpression of the PI3 K pathway promoting uncontrollable levels of cell proliferation. In addition only Class I PI3K has been discovered to be involved in human cancer due to its unique ability to produce phosphoinositide 3,4,5 trisphosphate (PIP3), which has been discovered to play a crucial role in human oncogenesis. The role of PIK3CA is lucubrated in breast cancer and gastric cancer, but is not well characterized in lung diseases. In this review, we summarized the common biology and mutations in PIK3CA with its related signaling pathways. Furthermore, we elucidated the PIK3CA heterogeneity in different domains, between various cancers and in different lung cancers. We also take a look at current inhibitors such as KP-372-1 (KP-1), KP-372-2 (KP-2), GSK690693, etc. in order to highlight potential treatment of PIK3CA mutations in human cancer and what directions future research should focus on. (C) 2016 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据